The present invention provides methods for high throughput screening and detection of nucleic acids from pathogens, such as SARS CoV-2, using nucleic acid amplification with nanoparticle binding complex formation and MRI or NMR detection. In certain embodiments, the MRI is three-dimensional MRI that simultaneously detects a plurality of amplified nucleic acid-nanoparticle complexes. In certain embodiments, the nucleic acids are amplified by isothermal LAMP techniques. In other embodiments, the nucleic acids are amplified by PCR. Methods of the invention are particularly useful rapid screening of large number of samples during pandemic situations.

The present invention includes compositions and methods for the detection of all known respiratory agents including Coronaviruses, and the recently discovered Sars-CoV-2, the agent of the CoVID Pandemic. The invention further includes detection of immune signatures of patients infected with a Coronavirus as well as other infectious agents.

Systems and a device for a pathogen detection system are described herein. For example, a pathogen detection system may include a pathogen detection device comprising an inlet, an outlet, and a reactive chamber; an imaging system comprising an excitation source and a fluorescence detection system; a substrate; and a heating element. In some examples, the pathogen detection system may be configured to detect one or more pathogens and/or viruses in a sample. For example, the pathogen detection device may receive a solution containing at least one of DNA or RNA and route the solution to the reactive chamber. Upon heating the solution, the pathogen detection device may further receive a probe containing one or more fluorescent dyes. The excitation source may excite the solution, and the detection system may detect an emission of the one or more fluorescent dyes.

A method for nucleic acid isolation comprising: receiving a binding moiety solution within a process chamber; mixing the binding moiety solution with a biological sample, within the process chamber, in order to produce a moiety-sample mixture; incubating the moiety-sample mixture during a time window, thereby producing a solution comprising a set of moiety-bound nucleic acid particles and a waste volume; separating the set of moiety-bound nucleic acid particles from the waste volume; washing the set of moiety-bound nucleic acid particles; and releasing a nucleic acid sample from the set of moiety-bound nucleic acid particles. The method preferably utilizes a binding moiety comprising at least one of poly(allylamine) and polypropylenimine tetramine dendrimer, both of which reversibly bind and unbind to nucleic acids based upon environmental pH.

The present invention provides a reagent and method for detecting a replication-competent lentivirus (RCL) by fluorescence quantitative real-time polymerase chain reaction (PCR). In particular, the present invention provides a primer and probe combination for detecting RCL, and a method for performing detection using said primer and probe; the present invention also provides a reagent kit comprising said primer and probe. The primer and probe combination of the present invention detects RCL with high amplification efficiency and good specificity, and can be used for RCL detection and RCL monitoring of clinical patient peripheral blood samples which may occur during a production process.

The present invention relates to a diagnostic assay for the virus causing severe acute respiratory syndrome Sars-CoV 2 (COVID-19, COVID-19; COVID-19-CoV-2) in humans (“COVID-19 virus”). In particular, the invention relates to a real-time quantitative PCR assay for the detection of COVID-19 virus using reverse transcription and polymerase chain reaction. Specifically, the qualitative assay is a TaqMan® assay using the primers and probes constructed based on the genome of the COVID-19 virus. The invention further relates to a diagnostic kit that comprises nucleic acid molecules for the detection of the COVID-19 virus.

A portable diagnostic device for performing the diagnosis of pathogens, such as viruses, bacteria, microorganisms, etc., by rapidly detecting their nucleic acids in a biological sample to be tested. Also, the use of the portable diagnostic device and the methods for detection of at least one nucleic acid sequence of interest implemented with the aid of the portable diagnostic device.

The oligonucleotide nanostructures enable pattern-recognized targeting of diseases, particularly useful as high-specificity detectors and inhibitors of viruses and toxins, such as for Dengue virus particles. The nanostructures include an oligonucleotide scaffold with a plurality of binders arranged in a pattern conforming to a plurality of surface epitopes of a target disease. Binding of the scaffolds to these surface epitopes has been shown to have inhibitory effects against the target disease. The scaffolds can also include functional domains that activate upon target binding. Assembly of the scaffolds can be achieved via annealing of separate oligonucleotide segments of predetermined length and sequence, which also advantageously define locations of binding domains in the resulting structure. This approach provides precise control over the spacing and orientation of epitope binding sites in the scaffold.

Provided are compositions and methods useful to the determination of whether a microbial contaminant is present in a biological therapeutic production process. Specifically, an artificial positive amplification control plasmid and unique quantitative PCR detection probe are provided, which enables the rapid and real-time detection of a false positive result.

Disclosed is a method for detecting virus particles in a sample, comprising the steps of: (a) incubating the sample with at least one virus-binding molecule bound to a solid phase; and (b) detecting binding of virus particles to the at least one virus-binding molecule bound to the solid phase. Also disclosed is a kit for use in this method.